We made direct noninvasive magnetic measurements of hepatic iron stores with a specially designed superconducting quantum-interference-device (SQUID) susceptometer in 20 normal subjects and in 110 patients with liver disease, iron deficiency, hereditary hemochromatosis, or transfusional iron overload. Magnetic in vivo measurements of liver non-heme iron were closely correlated with chemical in vitro measurements in liver-biopsy specimens (r = 0.98, P less than 10(-5) up to 115 mumol per gram of liver tissue (wet weight) or more. Magnetically determined storage-iron concentrations were below 6.0 mumol per gram in iron-deficient patients and normal men and premenopausal women, but they were raised (9.7 to 31.4 mumol) in 12 of 67 patients with liver disease and were greatly increased (22.9 to 117.7 mumol) in patients with untreated hereditary hemochromatosis or transfusional iron overload. Magnetic measurements of iron stores provide a new quantitative technique for early detection of hereditary hemochromatosis and for rapid evaluation of treatment regimens for transfusional iron overload.
This article has been cited by other articles:
Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N.
(2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 257S-298S
[Abstract][Full Text]
Siemonsen, S., Finsterbusch, J., Matschke, J., Lorenzen, A., Ding, X.-Q., Fiehler, J.
(2008). Age-Dependent Normal Values of T2* and T2' in Brain Parenchyma. Am. J. Neuroradiol.
29: 950-955
[Abstract][Full Text]
Angelucci, E., Barosi, G., Camaschella, C., Cappellini, M. D., Cazzola, M., Galanello, R., Marchetti, M., Piga, A., Tura, S.
(2008). Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. haematol
93: 741-752
[Abstract][Full Text]
Cohen, A. R., Glimm, E., Porter, J. B.
(2008). Effect of transfusional iron intake on response to chelation therapy in -thalassemia major. Blood
111: 583-587
[Abstract][Full Text]
Stumpf, J. L.
(2007). Deferasirox. Am J Health Syst Pharm
64: 606-616
[Abstract][Full Text]
VanOrden, H. E, Hagemann, T. M
(2006). Deferasirox--An Oral Agent for Chronic Iron Overload. The Annals of Pharmacotherapy
40: 1110-1117
[Abstract][Full Text]
Pennell, D. J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E. D., Tanner, M. A., Smith, G. C., Westwood, M. A., Wonke, B., Galanello, R.
(2006). Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood
107: 3738-3744
[Abstract][Full Text]
Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, P., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P., Alberti, D.
(2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood
107: 3455-3462
[Abstract][Full Text]
Iolascon, A., d'Apolito, M., Servedio, V., Cimmino, F., Piga, A., Camaschella, C.
(2006). Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood
107: 349-354
[Abstract][Full Text]
Wood, J. C., Enriquez, C., Ghugre, N., Tyzka, J. M., Carson, S., Nelson, M. D., Coates, T. D.
(2005). MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood
106: 1460-1465
[Abstract][Full Text]
Wang, Z. J., Lian, L., Chen, Q., Zhao, H., Asakura, T., Cohen, A. R.
(2005). 1/T2 and Magnetic Susceptibility Measurements in a Gerbil Cardiac Iron Overload Model. Radiology
234: 749-755
[Abstract][Full Text]
St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P., Olynyk, J. K., Pootrakul, P., Robins, E., Lindeman, R.
(2005). Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood
105: 855-861
[Abstract][Full Text]
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S.
(2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 287S-310S
[Abstract][Full Text]
Mariani, R, Arosio, C, Pelucchi, S, Grisoli, M, Piga, A, Trombini, P, Piperno, A
(2004). Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut
53: 756-758
[Abstract][Full Text]
Jensen, P. D., Jensen, F. T., Christensen, T., Eiskjaer, H., Baandrup, U., Nielsen, J. L.
(2003). Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood
101: 4632-4639
[Abstract][Full Text]
Brittenham, G. M., Badman, D. G.
(2003). Noninvasive measurement of iron: report of an NIDDK workshop. Blood
101: 15-19
[Abstract][Full Text]
Roetto, A., Merryweather-Clarke, A. T., Daraio, F., Livesey, K., Pointon, J. J., Barbabietola, G., Piga, A., Mackie, P. H., Robson, K. J. H., Camaschella, C.
(2002). A valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4?. Blood
100: 733-734
[Full Text]
Kushner, J. P., Porter, J. P., Olivieri, N. F.
(2001). Secondary Iron Overload. ASH Education Book
2001: 47-61
[Abstract][Full Text]
Angelucci, E., Brittenham, G. M., McLaren, C. E., Ripalti, M., Baronciani, D., Giardini, C., Galimberti, M., Polchi, P., Lucarelli, G.
(2000). Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. NEJM
343: 327-331
[Abstract][Full Text]
Andrews, N. C.
(1999). Disorders of Iron Metabolism. NEJM
341: 1986-1995
[Full Text]
Gangaidzo, I T, Moyo, V M, Saungweme, T, Khumalo, H, Charakupa, R M, Gomo, Z A R, Loyevsky, M, Stearman, R, Vaute, T L., Enquist, E G, Rouault, T A, Gordeuk, V R
(1999). Iron overload in urban Africans in the 1990s. Gut
45: 278-283
[Abstract][Full Text]
Olivieri, N. F.
(1999). The {beta}-Thalassemias. NEJM
341: 99-109
[Full Text]
Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R. G., McClelland, R. A., Burt, A. D., Fleming, K. A.
(1998). Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major. NEJM
339: 417-423
[Abstract][Full Text]
Angelucci, E., Giovagnoni, A., Valeri, G., Paci, E., Ripalti, M., Muretto, P., McLaren, C., Brittenham, G. M., Lucarelli, G.
(1997). Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. Blood
90: 4736-4742
[Abstract][Full Text]
Olivieri, N. F., Brittenham, G. M.
(1997). Iron-Chelating Therapy and the Treatment of Thalassemia. Blood
89: 739-761
[Full Text]
Olivieri, N. F., Brittenham, G. M., Matsui, D., Berkovitch, M., Blendis, L. M., Cameron, R. G., McClelland, R. A., Liu, P. P., Templeton, D. M., Koren, G.
(1995). Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major. NEJM
332: 918-922
[Abstract][Full Text]
Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., Harris, J. W.
(1994). Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. NEJM
331: 567-573
[Abstract][Full Text]
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., Cohen, A. R.
(1994). Survival in Medically Treated Patients with Homozygous {beta}-Thalassemia. NEJM
331: 574-578
[Abstract][Full Text]
Lowrey, C. H., Nienhuis, A. W.
(1993). Treatment with Azacitidine of Patients with End-Stage {beta}-Thalassemia. NEJM
329: 845-848
[Full Text]
Edwards, C. Q., Kushner, J. P.
(1993). Screening for Hemochromatosis. NEJM
328: 1616-1620
[Full Text]
Previous
